HHI places a market on a 0–10,000 concentration scale. The 2023 Merger Guidelines flag anything past 1,800 as highly concentrated; this observatory classifies with the more conservative 2,500 line.
HHI is withheld here — public firm-level data isn’t sufficient for a reliable calculation.
Evidence atlas
Source to public action route
40%
Public coverage0 share rows
Live evidence packetGap namedHHI stays withheld until public shares support it
Reusable rows661 sources, 0 share rows
Public actionEvidence buildPublish firm-level shares, ownership/control links, and market-definition notes before public agencies rely on private estimates.
Data
2023
Incomplete
Packet
66 rows
1 core source
Action
Evidence build
Public data gap
Public stake
Health care
Concentrated markets turn everyday access into private leverage.
Evidence posture
Data gap
66 reusable rows across 1 core source.
Government duty
Evidence build
Publish firm-level shares, ownership/control links, and market-definition notes before public agencies rely on private estimates.
HHI
Withheld
Classification unavailable
Top firm
N/A
Market share
CR4
N/A
Top 4 firms
Data status
Incomplete
Source availability
Confidence
High
Methodology limits
Review flags
1
Evidence build
Insufficient public market-share data for HHI calculation
Profile shows available public facts and missing data needed for HHI.
Observatory market brief
PBMs: aggregate concentration evidence, but not the individual shares required for HHI.
The public record reports only aggregate concentration facts. Individual shares do not close a firm-level distribution, so HHI remains withheld. The current public record does not provide a definition-stable firm-level HHI series.
01
Latest structure
HHI withheld
The public record reports only aggregate concentration facts. Individual shares do not close a firm-level distribution, so HHI remains withheld.
02
Published change
No comparable series
The current public record does not provide a definition-stable firm-level HHI series.
03
Evidence custody
4 custody records
4 records in the evidence custody chain, 0 latest share rows, 4 linked official records, and 2 related briefs support this profile. Status is incomplete with high confidence.
Comparison window
Series status
2023 evidence
The current public record does not provide a definition-stable firm-level HHI series.
Measured-market contextHHI withheldexcluded from HHI ranking
Public research question
Which individual firm shares and geographic boundaries are needed to move from aggregate concentration facts to a complete market screen?
Evidence build
Publish firm-level shares, ownership/control links, and market-definition notes before public agencies rely on private estimates.Open public-action route
Market-definition contract
Read the boundary before the metric.
This profile’s concentration claims apply only to the product, geography, denominator, and measurement basis documented below.
Agency definedhigh confidence2023 basis
Product boundary
Pharmacy benefit management services represented by prescription processing
Geographic boundary
United States
Measurement basis
FTC-reported aggregate shares of prescriptions processed
Denominator
U.S. prescriptions processed by the PBMs covered in the FTC public findings
Included
Top-three and top-six aggregate concentration facts
Excluded
Individual PBM shares sufficient to construct a complete firm distribution
Cross-market use
Not comparable
Time-series use
Snapshot only
Method note
Publish the FTC aggregate concentration facts and withhold HHI until individual citable PBM shares are available.
Top-three and top-six aggregates do not identify the individual firm shares needed to calculate HHI.
Boundary source
Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies
Federal Trade Commission · accessed 2026-05-16
Declared economy screen / navigation only
NAICS 524292 / Pharmacy benefit management and other third party administration of insurance and pension funds
2022 national industry HHI 1,633.5; this does not redefine or validate the market above.
The same 0-10,000 HHI scale does not make different product, geographic, or denominator definitions economically interchangeable. Cross-market HHI is a descriptive screen only.
Evidence timeline
Follow the profile from source record to public action.
Each profile should read like an inspectable research route: source access, concentration metric, participant table, official policy chronology, briefing, and the government question it creates.
Strong public profiles are navigable. This view connects the current market to sector peers, concentration peers, and disclosure-gap peers using the public metrics already in the observatory. Node size follows published HHI; withheld HHI uses the smallest marker.
Keep HHI, firm shares, trend, and evidence quality separate so researchers can inspect why this market is routed for review.
Review posture
Evidence build
Confidence
High confidence
Exact flags
1 visible
Screening rule
Review posture uses published concentration thresholds, trend direction, and evidence status as separate signals. It does not estimate consumer harm or establish legal liability.
Public implication
Publish firm-level shares, ownership/control links, and market-definition notes before public agencies rely on private estimates.
Evidence still needed
Firm-level shares and local ownership/control data
Public data incomplete
Data provenance
Methodology: Show aggregate public facts and withhold HHI until individual firm-level shares are public and citable.
Limitations: Profile shows available public facts and missing data needed for HHI.
Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies
Federal Trade Commission
agency report
Federal Trade Commission, FTC Releases Interim Staff Report on Prescription Drug Middlemen, July 9 2024.
A compact audit of whether the profile has enough public evidence to support action.
Build evidence
Freshness2023Latest source access May 16, 2026Coverage40%0 public share rows; HHI still withheldAPI routes8Filtered public JSON endpoints for reuseSource mix1agency report
Source mix
1 sources
agency report1
Missing evidence
Comparable local market definitions
Firm-level owner or operator shares
Acquisition, control, and property-management links
Public evidence packet
Jump from this market profile to the filtered machine-readable rows behind the public claim.